Back to Directory
Agalsidase Beta
Performance & EnduranceEnzyme replacement therapy for Fabry disease, recombinant alpha-galactosidase A.
Key Benefits
- ✓Treats Fabry disease
- ✓Reduces GL-3 accumulation
- ✓Slows disease progression
- ✓Improves cardiac function
- ✓Reduces pain crises
Dosing Information
Dosage Range
1 mg/kg
Frequency
Every 2 weeks
Typical Duration
Lifelong
Detailed Protocol
Administered via intravenous infusion every 2 weeks. Infusion center. Premedication may be needed. Lifelong therapy for Fabry patients.
About Agalsidase Beta
Agalsidase beta (Fabrazyme) is recombinant human alpha-galactosidase A for enzyme replacement in Fabry disease. Reduces substrate accumulation in this X-linked lysosomal storage disorder. FDA-approved.
Research Notes
FDA-approved in 2003 for Fabry disease. Significant improvements in cardiac and renal function. Reduces pain. Lifelong therapy required.
Potential Side Effects
- •Infusion reactions
- •Fever
- •Chills
- •IgG antibody development
- •Requires monitoring
Always consult with a healthcare professional before starting any peptide therapy.